Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.arbres.2021.05.010 http://scihub22266oqcxt.onion/10.1016/j.arbres.2021.05.010 34167859!?!34167859 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34167859&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Arch+Bronconeumol 2022 ; 58 (2): 150-158 Nephropedia Template TP {{tp|p=34167859|t=2022. Guia espanola para el manejo del asma (GEMA) version 5 1 Aspectos destacados y controversias |pdf=|usr=}}{{34167859}} gab.com Text Guia espanola para el manejo del asma (GEMA) version 5 1 Aspectos destacados y controversias JO: Arch Bronconeumol http://www.kidney.de/pget.php?&tw=1&pmid=34167859 #FOAvip In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FE(NO) cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis. Twit Text FOAVip Guia espanola para el manejo del asma (GEMA) version 5 1 Aspectos destacados y controversias ????Arch Bronconeumol http://www.kidney.de/pget.php?&tw=1&pmid=34167859 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34167859 #FOAvip English Wikipedia <ref>{{Cite pmid|34167859}}</ref> Guia espanola para el manejo del asma (GEMA) version 5 1 Aspectos destacados y controversias #MMPMID34167859 Plaza V; Alobid I; Alvarez C; Blanco M; Ferreira J; Garcia G; Gomez-Outes A; Gomez F; Hidalgo A; Korta J; Molina J; Pellegrini FJ; Perez M; Plaza J; Praena M; Quirce S; Sanz J Arch Bronconeumol 2022[Feb]; 58 (2): 150-158 PMID34167859show ga In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FE(NO) cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis. ?Guia espanola para el manejo del asma (GEMA) version 5 1 Aspectos des(epmc).pdf DeepDyve Pubget Overpricing